3-Hydroxy-3-methylglutaryl coenzyme
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, commonly known as statins, were introduced in the United States in 1987, and by 1997, approximately 86% of users of cholesterollowering drugs were using statins ( 1 ) . Several different statins inhibit colorectal carcinogenesis in rodent models ( 2 -6 ) . Results from studies of statin use and colorectal cancer are summarized in tbl1 Table 1 . The largest is the Molecular Epidemiology of Colorectal Cancer (MECC) study, a case-control study conducted in Israel ( 7 ) which included 1953 case patients diagnosed with colorectal cancer between 1998 and 2004 and 2015 control subjects. The MECC study found that statin use of more than 5 years was associated with a 47% reduction in risk of colorectal cancer ( 7 ) . There was no apparent association between colorectal cancer and use of bezafi brate, the most commonly used nonstatin cholesterollowering drug, although the statistical power to investigate this association was limited ( 7 ) . In contrast to results from the MECC study, none of the eight previous, small prospective studies found a statistically signifi cant association between statin use and the risk of colorectal cancer, although none of these studies specifi cally examined long-duration use ( 8 -15 ) . Four of these studies were randomized trials ( 8 -11 ) , and four were observational analyses that used prospec tively collected information from pharmacy databases ( 12 -15 ) .
We examined the association between use of cholesterol-lowering drugs and colorectal cancer incidence in the Cancer Prevention Study II (CPS-II) Nutrition Cohort during the period from the date of completion of a study questionnaire in 1997 through August 31, 2001. We considered overall use of cholesterol-lowering drugs to be a reasonable surrogate measure for use of statins because during this period, most users of cholesterol-lowering drugs took statins. The CPS-II Nutrition Cohort includes adults in the United States and is described in detail elsewhere ( 16 ) . The Emory University Institutional Review Board approved all aspects of the CPS-II Nutrition Cohort. Participants completed a questionnaire at enrollment in 1992 and were sent follow-up questionnaires to update exposure information and to ascertain newly diagnosed cancers in the fall of 1997, 1999, and 2001. For this analysis, follow-up began at completion of the 1997 questionnaire, because data from retail pharmacies in the United State indicate that approximately 86% of those on cholesterollowering drugs used statins in 1997, compared with 62% in 1992 ( 1 ) . After exclusions for history of colorectal cancer, loss to follow-up, and incomplete information, 132 136 participants remained for analysis. Among these participants, we ascertained 815 incident cases of colorectal cancer from the date of completion of the 1997 questionnaire through August 31, 2001. Cases of colorectal cancer were identifi ed by self-reports of cancer on the follow-up questionnaires (subsequently verifi ed by obtaining medical records or by state cancer registries) ( 16 ) or through linkage with the National Death Index ( 17 ) .
The 1997 questionnaire asked participants if they had taken any " cholesterollowering drugs " regularly during the past year and provided, as examples, the brand names for four statins commonly used at that time (lovastatin, pravastatin, simvastatin, and fl uvastatin) ( 1 ), as well as the brand names for the fi brate drug gemfi brozil and the bile acid-binding resin cholestyramine. Information on past use of cholesterol-lowering drugs was available from the 1992 questionnaire, which included a similar question.
We used Cox proportional hazards modeling ( 18 ) to calculate rate ratios for colorectal cancer incidence. We categorized use of cholesterol-lowering drugs as never, former, or current, with a timedependent variable initially defi ned by use reported in 1997 and updated by use reported in 1999. Current users were further categorized as having less than 5 years of drug use if they did not report use in 1992 or 5 years or more of drug use if they reported use in 1992. The proportional hazards assumption was verifi ed by modeling interactions between cholesterol-lowering drug exposure and a linear time variable.
As expected, the great majority of people who used cholesterol-lowering drugs in 1997 reported being told by a physician that they had " elevated cholesterol, " although elevated cholesterol was not uncommon among nonusers ( tbl2 Table 2 ). Users of cholesterol-lowering drugs were more likely than nonusers to report a history of heart attack, to use nonsteroidal anti-infl ammatory drugs regularly, to eat less red meat, and to have had colorectal endoscopy.
Current use of cholesterol-lowering drugs (rate ratio [RR] = 1.03, 95% confidence interval [CI] = 0.85 to 1.26) and even current use of 5 years or more (RR = 1.09, 95% CI = 0.83 to 1.43) was not associated with colorectal cancer ( tbl3 Table 3 ). No association between use of cholesterol-lowering drugs and colorectal cancer was observed in subgroups defi ned by sex, use of nonsteroidal antiinfl ammatory drugs, or history of colorectal endoscopy. Similarly, no association with use of cholesterol-lowering drugs was observed in analyses by stage of colorectal cancer at diagnosis or by anatomic subsite (proximal colon, distal colon, or rectum). Results were similar when the fi rst 2 years of follow-up were excluded (RR for ≥ 5 years of use = 1.05, 95% CI = 0.67 to 1.64).
Our null results are similar to those of previous small prospective studies ( 8 -15 ) but differ from the 47% reduction in risk associated with long-duration statin use in the large MECC casecontrol study ( 7 ) . Although our study population was from the United States and the MECC study population consisted predominantly of Israeli Jews, we know of no clear reason to expect a different association between statin use and colorectal cancer in these two populations. Variation in the types of statins used seems unlikely to fully account for the differing results. In the MECC study, pravastatin and simvastatin accounted for nearly all statin use, and each of these statins was associated with a similar reduction in risk, suggesting a general effect of statins, rather (Table continues) than of any one specifi c type. Moreover, pravastatin and simvastatin were the two most commonly prescribed statins in the United States in 1997 ( 1 ), the start of follow-up in our study. It is possible that selection bias or recall bias contributed to the reduction in risk observed in the MECC case-control study. Alternatively, because we examined use of all cholesterol-lowering drugs as a surrogate measure for statin use, misclassification of statin use could have obscured a modest reduction in risk in our study. * Percentages adjusted to the age distribution of the entire study population. Former users ( n = 5350) are not shown. METs = metabolic equivalents; NSAID = nonsteroidal anti-infl ammatory drug; HRT = hormone replacement therapy.
† Quintiles (g/day) for men are as follows: ≤ 180, >180 -≤ 320, >320 -≤ 480, >480 -≤ 560, and >560. Quintiles for women are as follows: ≤ 90, >90 -≤ 240, >240 -≤ 320, >320 -≤ 560, and >560. ‡ Had used HRT, but current use status at baseline was unknown. § Ever had elevated cholesterol, as self-reported by participants. 
